Vanda (VNDA) Q3 2026 Earnings Call Transcript

Vanda Pharmaceuticals reported Q3 2026 revenue of $69.8 million, up 24% year over year, with Fanapt sales rising 24% to $38.8 million and initial NEREUS sales of $1.6 million. Net loss was $22.6 million, unchanged year over year but down from $62.5 million in Q2; operating expenses fell 18% sequentially to $93.3 million. Management expects 2026 revenue above $240 million, while warning cash burn may exceed 2025 levels and HETLIOZ faces continued U.S. generic competition; BYSANTI is expected to launch in Q4 2026.

Analysis

VNDA’s quarter looks better in reported revenue than in repeatable cash generation. Fanapt prescription growth is the strongest operating signal, but the sequential revenue acceleration is flattered by HETLIOZ shipment timing and specialty-pharmacy stocking; the $7 million shipment recognized in Q3 is particularly vulnerable to a payback quarter. NEREUS adds upside optionality, not yet a reliable revenue base: sales are promotion-sensitive, wholesaler inventory has constrained recognized revenue, and the GLP-1 opportunity still depends on an FDA filing, review, and a commercially useful label. The 27% reduction on the primary vomiting endpoint—not the larger severe-subgroup effect—may be the more relevant adoption hurdle for prescribers and payers.

The key second-order risk is that portfolio growth and cost moderation may not arrive together. BYSANTI could improve franchise economics through a lower stated gross-to-net rate, but conversion from Fanapt takes time and may partly shift existing patients rather than create incremental demand; launch spending and manufacturing cash needs remain. Meanwhile, generic pressure on HETLIOZ and elevated 2026 cash burn make the $140.5 million cash balance a financing-risk watch item, not proof of a near-term raise. Do not extrapolate the sequential expense decline as a stable run rate.

Near term (days to weeks), expect noisy estimates around HETLIOZ channel normalization and BYSANTI launch timing. Over 1–3 months, Quimilza’s December FDA decision and the HETLIOZ jet-lag hearing are binary catalysts; neither should be valued as certain. Over 6–18 months, BYSANTI conversion, NEREUS label expansion, and cash consumption determine whether growth becomes self-funding. Contrarian angle: Fanapt prescription momentum is credible, but the market may over-credit headline revenue growth while underpricing launch execution and liquidity risk. No direct LLY read-through is material on these facts.

Key Decisions for Investors

• Avoid chasing VNDA on Q3 revenue growth. Wait for the next report to separate underlying HETLIOZ unit demand from channel restocking and shipment timing; a renewed decline in HETLIOZ sales alongside continued Fanapt prescription growth would confirm the portfolio-mix risk.
• Treat VNDA as a catalyst-driven, high-risk watch rather than a core long at this stage. Reassess after the December 12 Quimilza decision and evidence of BYSANTI launch availability; a delay or rejection would weaken the near-term product bridge, while approval alone does not establish commercial uptake.
• Track quarterly cash use, inventory/manufacturing payments, and any financing or guidance update. Escalating cash consumption without improving recurring product sales is the key thesis falsifier and should prompt a reduction in exposure; the article does not provide enough information to estimate runway.
• For NEREUS, wait for the FDA filing package and evidence of sustained demand beyond advertising pulses and initial channel stocking before underwriting GLP-1 revenue. Monitor primary-endpoint support, payer access, refill behavior, and recognized sales versus channel inventory; do not base a position on the severe-subgroup result alone.